Skip to main content
Smart Investors Daily
CT

NASDAQ · CTIC

CTI BioPharma Corp.

Healthcare · Biotechnology

$9.10

Up+$0.01 (+0.06%)

Updated Aug 15, 2026, 2:52 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.2B
P/E ratio
-11.46
Dividend yield
0.00%
52-week range
— – —
Volume
5.56M
Avg. volume
6.36M

Price performance

CTIC price history

1M range · 0 trading sessions · Daily adjusted prices

CTIC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CTIC news

The latest Smart Investors Daily articles mentioning CTIC.

CTIC research

Overview

Company profile and research snapshot.

Company profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$10.40
Implied upside
Analysts
CTIC recent ratings
DateFirmRatingTarget
May 24, 2023JMP SecuritiesMarket Perform
May 16, 2023SVB LeerinkMarket Perform
May 15, 2023StifelHold
May 11, 2023NeedhamHold
May 11, 2023JMP SecuritiesMarket Perform
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · May 23, 2023

Top 5 Health Care Stocks That Should Keep You Up At Night

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Cerevel Therapeutics appointed Susan Altschuller, as Chief Financial Officer. The company’s stock has a 52-week high of $41.46 . RSI Value: 71.46 CERE Price Action: Shares of Cerevel Therapeutics rose 4.7% to close at $34.00 on Monday. Voyager Therapeutics, Inc. (NASDAQ: VYGR) Voyager Therapeutics reported a year-over-year increase in first-quarter EPS and sales results. “Voyager started 2023 by ...

Benzinga · May 15, 2023

The Latest Analyst Ratings for CTI BioPharma

Analysts have provided the following ratings for CTI BioPharma (NASDAQ:CTIC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 These 5 analysts have an average price target of $8.82 versus the current price of CTI BioPharma at $8.925, implying downside. Below is a summary of how these 5 analysts rated CTI BioPharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the ...Full story available on Benzinga.com

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.